Grifols, (NASDAQ: GRFS) and Osiris Therapeutics (OTCMKTS:OSIR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, dividends, analyst recommendations and risk.
Grifols, pays an annual dividend of $0.28 per share and has a dividend yield of 1.2%. Osiris Therapeutics does not pay a dividend. Grifols, pays out 30.1% of its earnings in the form of a dividend.
This table compares Grifols, and Osiris Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
22.6% of Grifols, shares are held by institutional investors. Comparatively, 0.3% of Osiris Therapeutics shares are held by institutional investors. 44.6% of Osiris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This is a breakdown of recent recommendations and price targets for Grifols, and Osiris Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Risk and Volatility
Grifols, has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Comparatively, Osiris Therapeutics has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.
Earnings & Valuation
This table compares Grifols, and Osiris Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Grifols,||$4.48 billion||3.51||$603.60 million||$0.93||24.77|
|Osiris Therapeutics||$59.87 million||3.37||-$1.78 million||N/A||N/A|
Grifols, has higher revenue and earnings than Osiris Therapeutics.
Grifols, beats Osiris Therapeutics on 10 of the 12 factors compared between the two stocks.
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. It operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This segment offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. This segment serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by hospitals consisting of parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.
About Osiris Therapeutics
Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing. The Company’s products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company’s BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.
Receive News & Ratings for Grifols S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols S.A. and related companies with MarketBeat.com's FREE daily email newsletter.